19th Jan 2007 10:49
Isotron PLC19 January 2007 ISOTRON PLC 18 JANUARY 2007 NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, IN OR INTO OR FROM THE UNITED STATES, CANADA, AUSTRALIA, SOUTH AFRICA OR JAPAN INCREASED RECOMMENDED OFFER BY BREWIN DOLPHIN SECURITIES LTD ("BREWIN DOLPHIN") ON BEHALF OF SYNERGY HEALTHCARE PLC ("SYNERGY" or "THE COMPANY") FOR ISOTRON PLC ("ISOTRON") CANCELLATION OF LISTING Isotron plc announces that it has made application to the UK Listing Authorityfor the cancellation of the listing of Isotron Shares and similarly to theLondon Stock Exchange for the cancellation of Isotron's admission to trading.These applications are made at the request of Synergy Healthcare plc which hasnow acquired or has valid acceptances for the increased Recommended Offer inrespect of over 90 per cent of the Isotron's issued share capital. Thecancellation is anticipated to take effect on 2 March 2007. From that datetrading of Isotron Shares on the London Stock Exchange will cease. Furthermore, Synergy will today post compulsory acquisition notices to thoseIsotron Shareholders who have not yet accepted the Increased Recommended Offer,including notice of the anticipated cancellation of listing. Enquiries; Synergy Healthcare plc 01332 387 100 Richard Steeves, Chief Executive Ivan Jacques, Group Finance Director Brewin Dolphin Securities Ltd 0845 270 8600(financial adviser and broker to Synergy Healthcare plc) Mark Brady Matt Davis Andrew Emmott Financial Dynamics 0207 269 7156(PR adviser to Synergy Healthcare plc) David Yates Isotron plc 01793 891 891 John Barker, Chief Executive Paul Wynne, Finance Director JPMorgan Cazenove Ltd 020 7588 2828(financial adviser and broker to Isotron plc) Mark BreuerMichael Wentworth-StanleyJames MitfordAndrew Truscott Hudson Sandler 020 7796 4133(PR adviser to Isotron plc) Alistair Mackinnon-Musson Nicola Savage This announcement does not constitute or form part of, an offer or invitation topurchase or subscribe for any securities. The Offer is made solely by means ofthe Increased Recommended Offer Document and the Form of Acceptance accompanyingthe Increased Recommended Offer Document, which contain the full terms andconditions of the Offer including details of how it may be accepted. Brewin Dolphin is acting for Synergy Healthcare and for no-one else inconnection with the Offer and the increased Recommended Offer and will notregard any other person as its client nor be responsible to anyone other thanSynergy Healthcare for providing the protections afforded to clients of BrewinDolphin nor for providing advice in relation to the Offer and the IncreasedRecommended Offer or any matter referred to in this announcement. Brewin Dolphinis authorised and regulated by the Financial Services Authority. JPMorgan Cazenove, which is authorised and regulated in the United Kingdom bythe Financial Services Authority, is acting exclusively for Isotron and no oneelse in connection with the Increased Recommended Offer and will not beresponsible to anyone other than Isotron for providing the protections offeredto clients of JPMorgan Cazenove or for providing advice in relation to mattersreferred to in this announcement. The availability of the Offer and the Increased Recommended Offer to IsotronShareholders who are not resident in the United Kingdom may be affected by thelaws of the relevant jurisdictions in which they are located. Persons who arenot resident in the United Kingdom should inform themselves about and observe,applicable legal or regulatory requirements of their jurisdiction. The Offer and the Increased Recommended Offer will not be made, directly orindirectly, in or into, or by use of the mails, or by any means orinstrumentality (including, without limitation, telex, facsimile transmission,telephone, internet or other forms of electronic communication) of interstate orforeign commerce of, or by any facilities of a national securities exchange of,the United States, Canada, Australia, South Africa or Japan or any otherjurisdiction if to do so would constitute a violation of the relevant laws ofsuch jurisdiction and the Offer and the Increased Recommended Offer cannot beaccepted by any such use, means or instrumentality or otherwise from or withinthe United States, Canada, Australia, South Africa or Japan or any otherjurisdiction if to do so would constitute a violation of the relevant laws ofsuch jurisdiction. Accordingly, copies of this announcement are not being, andmust not be, mailed or otherwise forwarded, distributed or sent in or into orfrom any such jurisdiction. This information is provided by RNS The company news service from the London Stock ExchangeRelated Shares:
SYR.L